Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
US Department of Justice
Citi
Daiichi Sankyo
UBS
Johnson and Johnson
Moodys
QuintilesIMS
Farmers Insurance

Generated: May 27, 2018

DrugPatentWatch Database Preview

ESKALITH Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Eskalith, and when can generic versions of Eskalith launch?

Eskalith is a drug marketed by Noven Therap and Jds Pharms and is included in three NDAs.

The generic ingredient in ESKALITH is lithium carbonate. There are fifteen drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
Summary for ESKALITH
Drug patent expirations by year for ESKALITH
Medical Subject Heading (MeSH) Categories for ESKALITH
Synonyms for ESKALITH
10377-37-4 (mono-lithium salt)
12767-19-0
1312765-65-3
216964-61-3
2BMD2GNA4V
554-13-2
AC1L1WO8
AC1LANIP
AC1Q1U57
ACMC-209lmw
AKOS015904647
AN-45875
ANGC-554-13-2
ANW-32310
B7705
C07964
Camcolit
Candamide
Carbolite
Carbolith
Carbolithium
Carbolithium IFI
Carbolitium
Carbonic Acid Dilithium Salt
Carbonic acid lithium salt
Carbonic acid lithium salt (Li2CO3)
Carbonic acid, dilithium salt
Carbonic acid, lithium salt
Carbonic acid, lithium salt (1:2)
CCRIS 3153
Ceglution
CHEBI:6504
CHEMBL1200826
Cibalith-e
CLi2O3
CP 15467-61
CP-15,467-61
CP-15467-61
CP-1546761
CTK1G9703
D00801
D04UUH
Dilithium carbonate
Dilithium Carbonate, Dilithium Salt, Carbonic Acid
dilithium trioxidocarbonate
dilithium(1+) ion carbonate
diLithoTab CO3
Dilthium Carbonate
DTXSID1023784
Duralite
EC 209-062-5
EINECS 209-062-5
Eskalite
Eskalith (TN)
Eskalith CR
Eutimin
FT-0627895
GK3300
HSDB 3351
Hypnorex
I14-16784
I494
IN000219
IN006073
KS-0000025D
KSC269O0H
L0224
Li2CO3
Limas
Liskonum
Litard
Lithane
Lithea
Lithicarb
Lithinate
Lithionate
LITHIUM CARBONATE
Lithium carbonate (2:1)
Lithium carbonate (JP17/USP)
Lithium carbonate (Li2CO3)
Lithium carbonate [USAN:JAN]
Lithium carbonate [USAN:USP:JAN]
Lithium carbonate, 99% 500g
LITHIUM CARBONATE, ACS
Lithium carbonicum
Lithium Phasal
Lithium QD
Lithium, Reference Standard Solution
Lithiumcarbonat
Lithiumcarbonate
Lithizine
Litho-Carb
Lithobid
Lithobid (TN)
Lithobie
Lithonate
Lithotabs
Lithotabs Priadee
Liticar
LS-88061
LTBB002486
Manialith
Maniprex
MFCD00011084
Micalith
MolPort-003-927-648
Neurolepsin
NSC-16895
OR284070
Pfi-lithium
Pfl-Lithium
Phasal
Plenur
Priadel
Quilonorm
Quilonum retard
RL04084
RTR-019539
Teralithe
Teralithe [French]
TR-019539
TRA0065195
UNII-2BMD2GNA4V
XGZVUEUWXADBQD-UHFFFAOYSA-L
Zabuyelite

US Patents and Regulatory Information for ESKALITH

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Noven Therap ESKALITH lithium carbonate CAPSULE;ORAL 016860-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Jds Pharms ESKALITH lithium carbonate TABLET;ORAL 017971-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Jds Pharms ESKALITH CR lithium carbonate TABLET, EXTENDED RELEASE;ORAL 018152-001 Mar 29, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cerilliant
Citi
Teva
Fuji
Covington
QuintilesIMS
Accenture
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.